Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Shares are a Zacks #1 Rank (Strong Buy) and the company is poised for serious growth in the near future.
Company Description
Blount makes equipment and accessories for the forestry, lawn and garden, agriculture, construction and other similar markets. The company's main products are saw chains and guide bars for chainsaws.
Top Line Swells 39%
On Aug 9 Blount reported second quarter results that showed strong organic growth as well as successful acquisitions. Sales were up 39% to $201 million, a 25% increase without the acquisitions. Domestic sales are off less than a percent but international sales jumped 35%.
Earnings per share came in at $0.28, up 9 cents over the prior year to meet expectations. Blount has a strong earnings history though, surprising in each of the last 7 quarters leading up to this one.
Outlook Improves
The company raised its guidance for both the top and bottom lines in that press release as well. Analyst estimates moved up and are now averaging $1.21 for this year. Next year's Zacks Consensus Estimate rose 7 cents, to $1.37.
If Blount can hit those targets, year-over-year growth rates would be 42% and 13%, respectively.
And a Value?
Overpaying for growth is pretty common, but BLT is a value as well as a growth story. Shares are going for 12 times forward estimates, have a PEG around 0.9, and the P/S is 1.0.
Part of that value comes from the recent sell off, but with estimates still rising this is a patient investor's opportunity.
Bill Wilton is the Aggressive Growth Stock Strategist for Zacks.com. He is also the Editor in charge of the Zacks Small Cap Trader service
Read the full Snapshot Report on BLT